Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047197 | 1.00 | HSD11B1 (0.43) | HSD11B1NR3C1NR3C2HSD17B2HSD11B2 | |
| SCHEMBL13420373 | 1.00 | HSD11B1 (0.43) | HSD11B1NR3C1NR3C2HSD17B2HSD11B2 | |
| SCHEMBL13420651 | 1.00 | HSD11B1 (0.43) | HSD11B1NR3C1NR3C2HSD17B2HSD11B2 | |
| SCHEMBL13420414 | 0.90 | HSD11B1 (0.54) | HSD11B1NR3C1NR3C2HSD17B2HSD11B2 | |
| SCHEMBL13420918 | 0.90 | HSD11B1 (0.54) | HSD11B1NR3C1NR3C2HSD17B2HSD11B2 | |
| SCHEMBL13420653 | 0.90 | HSD11B1 (0.54) | HSD11B1NR3C1NR3C2HSD17B2HSD11B2 | |
| SCHEMBL13420380 | 0.88 | GPBAR1 (0.41) | HSD11B1SLC10A1GPBAR1 | |
| SCHEMBL14046882 | 0.88 | GPBAR1 (0.41) | HSD11B1SLC10A1GPBAR1 | |
| SCHEMBL13420644 | 0.88 | GPBAR1 (0.41) | HSD11B1SLC10A1GPBAR1 | |
| SCHEMBL13420650 | 0.87 | HSD11B1 (0.42) | HSD11B1SLC10A1ACHEGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | APP, BACE1, BACE2 | HSD11B1 661/4885NR3C1 2733/4885NR3C2 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.